94 related articles for article (PubMed ID: 6385655)
1. Pharmacokinetic and metabolic characteristics of ticlopidine in relation to its inhibitory properties on platelet function.
Picard-Fraire C
Agents Actions Suppl; 1984; 15():68-75. PubMed ID: 6385655
[No Abstract] [Full Text] [Related]
2. The effect of oral ticlopidine on arachidonic acid products in human platelets.
Bruno JJ; Chang LF; McSpadden MM; Yang D
Agents Actions Suppl; 1984; 15():76-87. PubMed ID: 6435408
[No Abstract] [Full Text] [Related]
3. [Evaluation of platelet aggregation in patients treated with ticlopidine].
Sbalzarini G; Carniti E; Fiorini L; Iezzi BG
Clin Ter; 1984 Nov; 111(3):247-50. PubMed ID: 6240365
[No Abstract] [Full Text] [Related]
4. Antiplatelet drugs and thrombosis prevention: ticlopidine in perspective.
de Gaetano G; Bertelé V
Arq Bras Cardiol; 1983 Dec; 41(6):425-7. PubMed ID: 6678584
[No Abstract] [Full Text] [Related]
5. [The antiaggregation effect of ticlopidine on blood platelets preliminary results and prospectives for studies in various diseases].
Andriani A; Chiappetta MG; Fabiani M; Mosiello G; Beni A
Clin Ter; 1983 Feb; 104(3):219-22. PubMed ID: 6345050
[No Abstract] [Full Text] [Related]
6. Comparative study of platelet aggregation measured with 3 different methods (photometric and impedance) in ticlopidine treated patients.
Lecrubier C; Girard P; Noire P; Samama M
Agents Actions Suppl; 1984; 15():60-7. PubMed ID: 6592946
[No Abstract] [Full Text] [Related]
7. Ticlopidine and platelet function.
Lecompte T; Lecrubier C; Potevin F; Samama M
Thromb Haemost; 1986 Jun; 55(3):437-8. PubMed ID: 3529484
[No Abstract] [Full Text] [Related]
8. Ticlopidine hydrochloride: relationship between dose, kinetics, plasma concentration and effect on platelet function.
Picard-Fraire C
Thromb Res Suppl; 1983; 4():119-28. PubMed ID: 6356462
[TBL] [Abstract][Full Text] [Related]
9. Overview: pharmacology of ticlopidine.
Gordon JL
Agents Actions Suppl; 1984; 15():108-15. PubMed ID: 6385643
[No Abstract] [Full Text] [Related]
10. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo effects of ticlopidine on human platelets: inhibition of fibrinogen binding by a mechanism independent of thromboxane formation.
Iovine C; d'Avenia V; Turco S; Mattioli PL; di Minno G
Agents Actions Suppl; 1984; 15():105-7. PubMed ID: 6592941
[No Abstract] [Full Text] [Related]
12. [The effects of ticlopidine on platelet aggregation: study on 13 atherosclerotic patients].
Lenci R; Galante A; Borzi M; Ariganello M; Sommariva L; Filice A; Cannata D
Clin Ter; 1983 Feb; 104(3):205-9. PubMed ID: 6861457
[No Abstract] [Full Text] [Related]
13. [Ticlopidine as something more than a platelet antiaggregant].
Villaverde C; Cánovas M; Padró T; Navarro C
Arch Farmacol Toxicol; 1984 Aug; 10(2):121-32. PubMed ID: 6517621
[No Abstract] [Full Text] [Related]
14. Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability.
Wong PC; Crain EJ; Watson CA; Hua J; Schumacher WA; Rehfuss R
Thromb Haemost; 2009 Jan; 101(1):108-15. PubMed ID: 19132196
[TBL] [Abstract][Full Text] [Related]
15. The in vitro effect of ticlopidine on fibrinogen and factor VIII binding to human platelets.
Lee H; Paton RC; Ruan C; Caen JP
Thromb Haemost; 1981 Oct; 46(3):590-2. PubMed ID: 6797089
[TBL] [Abstract][Full Text] [Related]
16. In vitro study of ticlopidine, as a model of antisickling action of platelet antiaggregant.
Sablayrolles M; Wajcman H; Castaigne JP; Labie D
Haematologia (Budap); 1984; 17(2):199-207. PubMed ID: 6534828
[TBL] [Abstract][Full Text] [Related]
17. Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects.
Jakubowski JA; Payne CD; Weerakkody GJ; Brandt JT; Farid NA; Li YG; Naganuma H; Lachno DR; Winters KJ
J Cardiovasc Pharmacol; 2007 Mar; 49(3):167-73. PubMed ID: 17414229
[TBL] [Abstract][Full Text] [Related]
18. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel.
Payne CD; Li YG; Small DS; Ernest CS; Farid NA; Jakubowski JA; Brandt JT; Salazar DE; Winters KJ
J Cardiovasc Pharmacol; 2007 Nov; 50(5):555-62. PubMed ID: 18030066
[TBL] [Abstract][Full Text] [Related]
19. Effects of 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride (Ticlopidine), a platelet aggregation inhibitor, on blood-borne metastasis.
Kohga S; Kinjo M; Tanaka K; Ogawa H; Ishihara M; Tanaka N
Cancer Res; 1981 Nov; 41(11 Pt 1):4710-4. PubMed ID: 7306988
[TBL] [Abstract][Full Text] [Related]
20. [Platelet aggregation and antiaggregant drugs].
Andriani A; Chiappetta MG; Fabiani M
Recenti Prog Med; 1982 Nov; 73(5):537-42. PubMed ID: 6761807
[No Abstract] [Full Text] [Related]
[Next] [New Search]
